{"id":30981,"date":"2023-02-27T00:00:00","date_gmt":"2023-02-27T00:00:00","guid":{"rendered":"https:\/\/basquetrade.spri.eus\/vivebiotech-etorkizuneko-medikuntzarantz-aurrera-pausuak-ematen-ditu-bere-terapia-genetikoren-eskutik\/"},"modified":"2023-02-27T00:00:00","modified_gmt":"2023-02-27T00:00:00","slug":"vivebiotech-etorkizuneko-medikuntzarantz-aurrera-pausuak-ematen-ditu-bere-terapia-genetikoren-eskutik","status":"publish","type":"post","link":"https:\/\/basquetrade.spri.eus\/eu\/vivebiotech-etorkizuneko-medikuntzarantz-aurrera-pausuak-ematen-ditu-bere-terapia-genetikoren-eskutik\/","title":{"rendered":"VIVEbiotech etorkizuneko medikuntzarantz aurrera pausuak ematen ditu bere terapia genetikoren eskutik"},"content":{"rendered":"<p><strong>Terapia genetikoak etorkizuneko medikuntzaren abangoardia dira. Alor berritzaile horretan 2015etik dihardu <a href=\"https:\/\/www.vivebiotech.com\" target=\"_blank\" rel=\"noopener\">VIVEbiotech<\/a> empresa gipuzkoarrak, eta, gaur egun, Estatuan egiaztatutako enpresa bakarra da entsegu kliniko komertzialetarako bektore lentibiralak ekoizteko.<\/strong><\/p>\n<p>Zehazki, konpainiak garatutako ikerketa-ildoa minbizi hematologiko mota batzuk sendatzera bideratuta dago, hala nola leuzemiak, linfomak, mieloma eta gaixotasun arraroak.&#8221; Neurrira egindakoak eta malgutasuna duten bektore lentibiralak garatzeko eta ekoizteko beharrezko gaitasuna dugu, garapen-fase goiztiarrenetatik eskala komertzialeko produkzioraino&#8221;, diote enpresatik.<\/p>\n<p>Vivebiotech sortutako bektore lentikularrak funtsezkoak dira jatorri genetikoko gaixotasunen eta minbiziaren aurkako terapien eraginkortasuna bermatzeko. Bere ikerketa-lan arrakastatsuaren adibide gisa, Lentisoma &#8216;teknologiari esker patente bat lortu izana dago. Proiektu horren bidez, Europako Batzordeak EASM agentziaren bidez ematen duen &#8220;Proyecto Excente&#8221; zigilua ere jaso du.<\/p>\n<p>Teknologia horren ezaugarririk nabarmenena zelulen genoman txertatzen ez dela da. Ekintza-mekanismo berritzaile horrek hainbat abantailak ematen ditu &#8220;segurtasunari eta eraginkortasunari dagokienez, gaur egun erabiltzen diren bektoreekin alderatzen badira&#8221;, diote. &#8220;Gure konpainiako I+G saila hainbat berrikuntza-ildotan ari da lanean, lortutako emaitzak gure bezeroei transferitzeko&#8221;, gehitzen dute VIVEbiotech-tik.<\/p>\n<p>Konpainiak sortutako bektoreei dagokionez, hauek material genetikoa zelulen nukleora sartzeko tresna gisa balio dute eta era honetan, gaixotasunak sendatu ahal izateko baliabide bihurtzen dira. ViveBiotecheko arduradunen arabera, onura horri gehitu behar zaio zelula pazientearengandik ateratzeko aukera, zelula hori aldatuko duten geneak sartzeko eta, berriz gorputzean sartzean, tumore-zelulei erasotzea lortzeko.<\/p>\n<p>VIVEbiotech 3.000 metro karratuko instalazio abangoardistak ditu eta zazpi areto zuri Miramongo Parke Teknologikoan, baita goi-mailako prestakuntza duten 85 profesionalez osatutako talde bat ere, birologoen adituekin batera. Bere ikerketa-ibilbide luzean, Vivebiotechek nazioarteko 25 proiektutan parte hartu du medikuntza pertsonalizatuan eta doitasunean aurrera egiteko helburuarekin. Bere azken proiektuetako bat Japoniako farmazia-talde batekin batera egin du, terapia genikoaren bidez minbiziari aurre egiteko.<\/p>\n<p><strong>info+: <a href=\"https:\/\/www.vivebiotech.com\" target=\"_blank\" rel=\"noopener\">vivebiotech.com<\/a><\/strong><\/p>\n<p><iframe loading=\"lazy\" title=\"VIVEbiotech company presentation\" width=\"1200\" height=\"675\" src=\"https:\/\/www.youtube.com\/embed\/PR38AU81cGI?start=4&#038;feature=oembed\" frameborder=\"0\" allow=\"accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share\" referrerpolicy=\"strict-origin-when-cross-origin\" allowfullscreen><\/iframe><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Terapia genetikoak etorkizuneko medikuntzaren abangoardia dira. Alor berritzaile horretan 2015etik dihardu VIVEbiotech empresa gipuzkoarrak, eta, gaur egun, Estatuan egiaztatutako enpresa bakarra da entsegu kliniko komertzialetarako bektore lentibiralak ekoizteko. Zehazki, konpainiak garatutako ikerketa-ildoa minbizi hematologiko mota batzuk sendatzera bideratuta dago, hala nola leuzemiak, linfomak, mieloma eta gaixotasun arraroak.&#8221; Neurrira egindakoak eta malgutasuna duten bektore lentibiralak garatzeko &#8230; <a title=\"VIVEbiotech etorkizuneko medikuntzarantz aurrera pausuak ematen ditu bere terapia genetikoren eskutik\" class=\"read-more\" href=\"https:\/\/basquetrade.spri.eus\/eu\/vivebiotech-etorkizuneko-medikuntzarantz-aurrera-pausuak-ematen-ditu-bere-terapia-genetikoren-eskutik\/\" aria-label=\"Read more about VIVEbiotech etorkizuneko medikuntzarantz aurrera pausuak ematen ditu bere terapia genetikoren eskutik\">Read more<\/a><\/p>\n","protected":false},"author":0,"featured_media":18082,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[307],"tags":[],"paises":[582],"sectores":[370],"class_list":["post-30981","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-berriak","paises-beste-herriak","sectores-beste-sektore-batzuk"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v25.9 (Yoast SEO v25.9) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>VIVEbiotech etorkizuneko medikuntzarantz aurrera pausuak ematen ditu bere terapia genetikoren eskutik - Basque Trade &amp; Investment<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.spri.eus\/nazioartekotzea-komunikazioa\/vivebiotech-etorkizuneko-medikuntzarantz-aurrera-pausuak-ematen-ditu-bere-terapia-genetikoren-eskutik\/\" \/>\n<meta property=\"og:locale\" content=\"eu_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"VIVEbiotech etorkizuneko medikuntzarantz aurrera pausuak ematen ditu bere terapia genetikoren eskutik\" \/>\n<meta property=\"og:description\" content=\"Terapia genetikoak etorkizuneko medikuntzaren abangoardia dira. Alor berritzaile horretan 2015etik dihardu VIVEbiotech empresa gipuzkoarrak, eta, gaur egun, Estatuan egiaztatutako enpresa bakarra da entsegu kliniko komertzialetarako bektore lentibiralak ekoizteko. Zehazki, konpainiak garatutako ikerketa-ildoa minbizi hematologiko mota batzuk sendatzera bideratuta dago, hala nola leuzemiak, linfomak, mieloma eta gaixotasun arraroak.&#8221; Neurrira egindakoak eta malgutasuna duten bektore lentibiralak garatzeko ... Read more\" \/>\n<meta property=\"og:url\" content=\"https:\/\/basquetrade.spri.eus\/vivebiotech-avanza-hacia-la-medicina-del-fututo-de-la-mano-de-la-terapia-gen-tica\/\" \/>\n<meta property=\"og:site_name\" content=\"Basque Trade &amp; Investment\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-27T00:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/basquetrade.spri.eus\/\/wp-content\/uploads\/2025\/01\/2302-spri-emprendimiento-vivebiotech-portada-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"900\" \/>\n\t<meta property=\"og:image:height\" content=\"500\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/basquetrade.spri.eus\/vivebiotech-avanza-hacia-la-medicina-del-fututo-de-la-mano-de-la-terapia-gen-tica\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/basquetrade.spri.eus\/vivebiotech-avanza-hacia-la-medicina-del-fututo-de-la-mano-de-la-terapia-gen-tica\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"VIVEbiotech etorkizuneko medikuntzarantz aurrera pausuak ematen ditu bere terapia genetikoren eskutik\",\"datePublished\":\"2023-02-27T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/basquetrade.spri.eus\/vivebiotech-avanza-hacia-la-medicina-del-fututo-de-la-mano-de-la-terapia-gen-tica\/\"},\"wordCount\":290,\"publisher\":{\"@id\":\"https:\/\/basquetrade.spri.eus\/#organization\"},\"image\":{\"@id\":\"https:\/\/basquetrade.spri.eus\/vivebiotech-avanza-hacia-la-medicina-del-fututo-de-la-mano-de-la-terapia-gen-tica\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/basquetrade.spri.eus\/\/wp-content\/uploads\/2025\/01\/2302-spri-emprendimiento-vivebiotech-portada-scaled.jpg\",\"articleSection\":[\"Berriak\"],\"inLanguage\":\"eu-ES\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/basquetrade.spri.eus\/vivebiotech-avanza-hacia-la-medicina-del-fututo-de-la-mano-de-la-terapia-gen-tica\/\",\"url\":\"https:\/\/basquetrade.spri.eus\/vivebiotech-avanza-hacia-la-medicina-del-fututo-de-la-mano-de-la-terapia-gen-tica\/\",\"name\":\"VIVEbiotech etorkizuneko medikuntzarantz aurrera pausuak ematen ditu bere terapia genetikoren eskutik - Basque Trade &amp; Investment\",\"isPartOf\":{\"@id\":\"https:\/\/basquetrade.spri.eus\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/basquetrade.spri.eus\/vivebiotech-avanza-hacia-la-medicina-del-fututo-de-la-mano-de-la-terapia-gen-tica\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/basquetrade.spri.eus\/vivebiotech-avanza-hacia-la-medicina-del-fututo-de-la-mano-de-la-terapia-gen-tica\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/basquetrade.spri.eus\/\/wp-content\/uploads\/2025\/01\/2302-spri-emprendimiento-vivebiotech-portada-scaled.jpg\",\"datePublished\":\"2023-02-27T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/basquetrade.spri.eus\/vivebiotech-avanza-hacia-la-medicina-del-fututo-de-la-mano-de-la-terapia-gen-tica\/#breadcrumb\"},\"inLanguage\":\"eu-ES\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/basquetrade.spri.eus\/vivebiotech-avanza-hacia-la-medicina-del-fututo-de-la-mano-de-la-terapia-gen-tica\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"eu-ES\",\"@id\":\"https:\/\/basquetrade.spri.eus\/vivebiotech-avanza-hacia-la-medicina-del-fututo-de-la-mano-de-la-terapia-gen-tica\/#primaryimage\",\"url\":\"https:\/\/basquetrade.spri.eus\/\/wp-content\/uploads\/2025\/01\/2302-spri-emprendimiento-vivebiotech-portada-scaled.jpg\",\"contentUrl\":\"https:\/\/basquetrade.spri.eus\/\/wp-content\/uploads\/2025\/01\/2302-spri-emprendimiento-vivebiotech-portada-scaled.jpg\",\"width\":900,\"height\":500},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/basquetrade.spri.eus\/vivebiotech-avanza-hacia-la-medicina-del-fututo-de-la-mano-de-la-terapia-gen-tica\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Portada\",\"item\":\"https:\/\/basquetrade.spri.eus\/eu\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"VIVEbiotech etorkizuneko medikuntzarantz aurrera pausuak ematen ditu bere terapia genetikoren eskutik\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/basquetrade.spri.eus\/#website\",\"url\":\"https:\/\/basquetrade.spri.eus\/\",\"name\":\"Basque Trade &amp; Investment\",\"description\":\"Agencia Vasca de Internacionalizaci\u00f3n \u2013 Basque Trade &amp; Investment\",\"publisher\":{\"@id\":\"https:\/\/basquetrade.spri.eus\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/basquetrade.spri.eus\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"eu-ES\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/basquetrade.spri.eus\/#organization\",\"name\":\"Basque Trade &amp; Investment\",\"url\":\"https:\/\/basquetrade.spri.eus\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"eu-ES\",\"@id\":\"https:\/\/basquetrade.spri.eus\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/basquetrade.spri.eus\/\/wp-content\/uploads\/2025\/04\/head-logo-BasqueTrade.jpg\",\"contentUrl\":\"https:\/\/basquetrade.spri.eus\/\/wp-content\/uploads\/2025\/04\/head-logo-BasqueTrade.jpg\",\"width\":230,\"height\":100,\"caption\":\"Basque Trade &amp; Investment\"},\"image\":{\"@id\":\"https:\/\/basquetrade.spri.eus\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"VIVEbiotech etorkizuneko medikuntzarantz aurrera pausuak ematen ditu bere terapia genetikoren eskutik - Basque Trade &amp; Investment","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.spri.eus\/nazioartekotzea-komunikazioa\/vivebiotech-etorkizuneko-medikuntzarantz-aurrera-pausuak-ematen-ditu-bere-terapia-genetikoren-eskutik\/","og_locale":"eu_ES","og_type":"article","og_title":"VIVEbiotech etorkizuneko medikuntzarantz aurrera pausuak ematen ditu bere terapia genetikoren eskutik","og_description":"Terapia genetikoak etorkizuneko medikuntzaren abangoardia dira. Alor berritzaile horretan 2015etik dihardu VIVEbiotech empresa gipuzkoarrak, eta, gaur egun, Estatuan egiaztatutako enpresa bakarra da entsegu kliniko komertzialetarako bektore lentibiralak ekoizteko. Zehazki, konpainiak garatutako ikerketa-ildoa minbizi hematologiko mota batzuk sendatzera bideratuta dago, hala nola leuzemiak, linfomak, mieloma eta gaixotasun arraroak.&#8221; Neurrira egindakoak eta malgutasuna duten bektore lentibiralak garatzeko ... Read more","og_url":"https:\/\/basquetrade.spri.eus\/vivebiotech-avanza-hacia-la-medicina-del-fututo-de-la-mano-de-la-terapia-gen-tica\/","og_site_name":"Basque Trade &amp; Investment","article_published_time":"2023-02-27T00:00:00+00:00","og_image":[{"width":900,"height":500,"url":"https:\/\/basquetrade.spri.eus\/\/wp-content\/uploads\/2025\/01\/2302-spri-emprendimiento-vivebiotech-portada-scaled.jpg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/basquetrade.spri.eus\/vivebiotech-avanza-hacia-la-medicina-del-fututo-de-la-mano-de-la-terapia-gen-tica\/#article","isPartOf":{"@id":"https:\/\/basquetrade.spri.eus\/vivebiotech-avanza-hacia-la-medicina-del-fututo-de-la-mano-de-la-terapia-gen-tica\/"},"author":{"name":"","@id":""},"headline":"VIVEbiotech etorkizuneko medikuntzarantz aurrera pausuak ematen ditu bere terapia genetikoren eskutik","datePublished":"2023-02-27T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/basquetrade.spri.eus\/vivebiotech-avanza-hacia-la-medicina-del-fututo-de-la-mano-de-la-terapia-gen-tica\/"},"wordCount":290,"publisher":{"@id":"https:\/\/basquetrade.spri.eus\/#organization"},"image":{"@id":"https:\/\/basquetrade.spri.eus\/vivebiotech-avanza-hacia-la-medicina-del-fututo-de-la-mano-de-la-terapia-gen-tica\/#primaryimage"},"thumbnailUrl":"https:\/\/basquetrade.spri.eus\/\/wp-content\/uploads\/2025\/01\/2302-spri-emprendimiento-vivebiotech-portada-scaled.jpg","articleSection":["Berriak"],"inLanguage":"eu-ES"},{"@type":"WebPage","@id":"https:\/\/basquetrade.spri.eus\/vivebiotech-avanza-hacia-la-medicina-del-fututo-de-la-mano-de-la-terapia-gen-tica\/","url":"https:\/\/basquetrade.spri.eus\/vivebiotech-avanza-hacia-la-medicina-del-fututo-de-la-mano-de-la-terapia-gen-tica\/","name":"VIVEbiotech etorkizuneko medikuntzarantz aurrera pausuak ematen ditu bere terapia genetikoren eskutik - Basque Trade &amp; Investment","isPartOf":{"@id":"https:\/\/basquetrade.spri.eus\/#website"},"primaryImageOfPage":{"@id":"https:\/\/basquetrade.spri.eus\/vivebiotech-avanza-hacia-la-medicina-del-fututo-de-la-mano-de-la-terapia-gen-tica\/#primaryimage"},"image":{"@id":"https:\/\/basquetrade.spri.eus\/vivebiotech-avanza-hacia-la-medicina-del-fututo-de-la-mano-de-la-terapia-gen-tica\/#primaryimage"},"thumbnailUrl":"https:\/\/basquetrade.spri.eus\/\/wp-content\/uploads\/2025\/01\/2302-spri-emprendimiento-vivebiotech-portada-scaled.jpg","datePublished":"2023-02-27T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/basquetrade.spri.eus\/vivebiotech-avanza-hacia-la-medicina-del-fututo-de-la-mano-de-la-terapia-gen-tica\/#breadcrumb"},"inLanguage":"eu-ES","potentialAction":[{"@type":"ReadAction","target":["https:\/\/basquetrade.spri.eus\/vivebiotech-avanza-hacia-la-medicina-del-fututo-de-la-mano-de-la-terapia-gen-tica\/"]}]},{"@type":"ImageObject","inLanguage":"eu-ES","@id":"https:\/\/basquetrade.spri.eus\/vivebiotech-avanza-hacia-la-medicina-del-fututo-de-la-mano-de-la-terapia-gen-tica\/#primaryimage","url":"https:\/\/basquetrade.spri.eus\/\/wp-content\/uploads\/2025\/01\/2302-spri-emprendimiento-vivebiotech-portada-scaled.jpg","contentUrl":"https:\/\/basquetrade.spri.eus\/\/wp-content\/uploads\/2025\/01\/2302-spri-emprendimiento-vivebiotech-portada-scaled.jpg","width":900,"height":500},{"@type":"BreadcrumbList","@id":"https:\/\/basquetrade.spri.eus\/vivebiotech-avanza-hacia-la-medicina-del-fututo-de-la-mano-de-la-terapia-gen-tica\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Portada","item":"https:\/\/basquetrade.spri.eus\/eu\/"},{"@type":"ListItem","position":2,"name":"VIVEbiotech etorkizuneko medikuntzarantz aurrera pausuak ematen ditu bere terapia genetikoren eskutik"}]},{"@type":"WebSite","@id":"https:\/\/basquetrade.spri.eus\/#website","url":"https:\/\/basquetrade.spri.eus\/","name":"Basque Trade &amp; Investment","description":"Agencia Vasca de Internacionalizaci\u00f3n \u2013 Basque Trade &amp; Investment","publisher":{"@id":"https:\/\/basquetrade.spri.eus\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/basquetrade.spri.eus\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"eu-ES"},{"@type":"Organization","@id":"https:\/\/basquetrade.spri.eus\/#organization","name":"Basque Trade &amp; Investment","url":"https:\/\/basquetrade.spri.eus\/","logo":{"@type":"ImageObject","inLanguage":"eu-ES","@id":"https:\/\/basquetrade.spri.eus\/#\/schema\/logo\/image\/","url":"https:\/\/basquetrade.spri.eus\/\/wp-content\/uploads\/2025\/04\/head-logo-BasqueTrade.jpg","contentUrl":"https:\/\/basquetrade.spri.eus\/\/wp-content\/uploads\/2025\/04\/head-logo-BasqueTrade.jpg","width":230,"height":100,"caption":"Basque Trade &amp; Investment"},"image":{"@id":"https:\/\/basquetrade.spri.eus\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/basquetrade.spri.eus\/eu\/wp-json\/wp\/v2\/posts\/30981","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/basquetrade.spri.eus\/eu\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/basquetrade.spri.eus\/eu\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/basquetrade.spri.eus\/eu\/wp-json\/wp\/v2\/comments?post=30981"}],"version-history":[{"count":0,"href":"https:\/\/basquetrade.spri.eus\/eu\/wp-json\/wp\/v2\/posts\/30981\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/basquetrade.spri.eus\/eu\/wp-json\/wp\/v2\/media\/18082"}],"wp:attachment":[{"href":"https:\/\/basquetrade.spri.eus\/eu\/wp-json\/wp\/v2\/media?parent=30981"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/basquetrade.spri.eus\/eu\/wp-json\/wp\/v2\/categories?post=30981"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/basquetrade.spri.eus\/eu\/wp-json\/wp\/v2\/tags?post=30981"},{"taxonomy":"paises","embeddable":true,"href":"https:\/\/basquetrade.spri.eus\/eu\/wp-json\/wp\/v2\/paises?post=30981"},{"taxonomy":"sectores","embeddable":true,"href":"https:\/\/basquetrade.spri.eus\/eu\/wp-json\/wp\/v2\/sectores?post=30981"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}